Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.40 |
| ▸ | MTTP | P55157 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454644 | 1.00 | TACR1 (0.43) | TACR1ALDH1A1HSP90AA1HSP90AB1TNFRSF1A | |
| SCHEMBL4450290 | 0.90 | TNFRSF1A (0.41) | ALDH1A1TNFRSF1AMTTPKMT2AKCNH2 | |
| SCHEMBL4450295 | 0.90 | TNFRSF1A (0.41) | ALDH1A1TNFRSF1AMTTPKMT2AKCNH2 | |
| SCHEMBL4446586 | 0.80 | TNFRSF1A (0.46) | ALDH1A1TNFRSF1AMAPTKMT2AKCNH2 | |
| SCHEMBL4446583 | 0.80 | TNFRSF1A (0.46) | ALDH1A1TNFRSF1AMAPTKMT2AKCNH2 | |
| SCHEMBL4443078 | 0.79 | TNFRSF1A (0.46) | ALDH1A1TNFRSF1AMAPTKMT2A | |
| SCHEMBL3638466 | 0.79 | TNFRSF1A (0.46) | ALDH1A1TNFRSF1AMAPTKMT2A | |
| SCHEMBL4450981 | 0.79 | TNFRSF1A (0.45) | ALDH1A1TNFRSF1AMAPTKMT2AKCNH2 | |
| SCHEMBL4450978 | 0.79 | TNFRSF1A (0.45) | ALDH1A1TNFRSF1AMAPTKMT2AKCNH2 | |
| SCHEMBL4456783 | 0.77 | MEN1 (0.47) | ALDH1A1TNFRSF1ATSHRKMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | TACR1 541/4885ALDH1A1 2335/4885HSP90AA1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.